Detalhe da pesquisa
1.
Peripheral T cell expansion predicts tumour infiltration and clinical response.
Nature
; 579(7798): 274-278, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32103181
2.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artigo
Inglês
| MEDLINE | ID: mdl-30297397
3.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artigo
Inglês
| MEDLINE | ID: mdl-27979383
4.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lancet Oncol
; 18(3): e143-e152, 2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28271869
5.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
; 387(10030): 1837-46, 2016 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-26970723
6.
Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab.
Eur J Clin Pharmacol
; 77(7): 1065-1066, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33415499
7.
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
J Clin Oncol
; : JCO2302166, 2024 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38552197
8.
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.
Clin Pharmacol Ther
; 113(4): 851-858, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36606486
9.
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
; 29(22): 4596-4605, 2023 11 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37702716
10.
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
J Immunother Cancer
; 11(10)2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37903590
11.
Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study.
AAPS J
; 24(3): 58, 2022 04 28.
Artigo
Inglês
| MEDLINE | ID: mdl-35484442
12.
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
Clin Transl Sci
; 15(1): 141-157, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34582105
13.
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Clin Transl Sci
; 15(1): 130-140, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34432389
14.
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Clin Lung Cancer
; 23(1): 21-33, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34226144
15.
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
Cancer Cell
; 40(3): 289-300.e4, 2022 03 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35216676
16.
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
PLoS One
; 16(2): e0246486, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33534859
17.
Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
Cancer Chemother Pharmacol
; 88(2): 211-221, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33904970
18.
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
CPT Pharmacometrics Syst Pharmacol
; 10(10): 1171-1182, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34270868
19.
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
JCO Precis Oncol
; 5: 827-838, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34994614
20.
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
J Immunother Cancer
; 9(3)2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33737340